Liquid biopsy

Paving the way for liquid biopsy

Description the way for liquid biopsy

Realize the full potential of liquid biopsy

Liquid biopsy is a less invasive method that limits the need for tissue. Using a simple biofluid sample, you can detect and monitor biomarkers of disease more frequently and efficiently.
Although liquid biopsy offers huge potential, wide adoption has been hindered by lack of clinical validation, sensitivity, specificity, standardization and scalability.
At QIAGEN, our mission is to speed up the development and application of liquid biopsy so you have the best tools and services to continue improving patients’ lives.

Innovation for progress

To drive the adoption of liquid biopsy in clinical and research laboratories, we have applied years of experience in the field to develop a dedicated Sample to Insight workflow. From sample collection to data interpretation – we provide the most robust technologies and resources to help you discover, detect and validate biomarkers for all three emerging liquid biopsy approaches: circulating cell-free nucleic acids, CTCs and exosomes.

Latest
–
Get news, updates and stories

EV biomarker webinar on-demand

The path from exosomes and EV biomarker research to real-world application is not always easy. That’s why we’ve asked four experts to share their insights with us. Watch our webinar on-demand to learn more.

Watch now

A Sample to Insight liquid biopsy workflow

Let us do the heavy lifting

Use our expert-led service solutions and get more time to spend on your interests.

Browse services

Featured
–
Dive deeper into liquid biopsy

Explore our Cancer Research Hub

Accelerate your journey to insights and help conquer cancer

VISIT HUB

FAQs – Quick answers and insights

General

What is a liquid biopsy?

A quick, non-invasive procedure that limits the need for surgical biopsy. It allows biomarkers for diseases such as cancer to be discovered in biofluids such as blood and urine, allowing for better disease detection and management. We offer a comprehensive portfolio of solutions in the field of liquid biopsy solutions covering the most important analytes: circulating tumor cells, exosomes and circulating cell-free nucleic acids.

What are the advantage and challenges of liquid biopsy?

Liquid biopsies can be useful when a tissue sample is limited or hard to reach and if regular monitoring is needed. The main challenges include: detecting a low amount of analytes in a high background and a lack of standardization. To overcome these, we have developed a comprehensive portfolio of liquid biopsy solutions to meet your changing needs.

We offer:

PAXgene technology for reliable sample collection and stabilization
Optimized sample preparation kits for isolating ccfDNA, ccfRNA, exosomes and CTCs from various biofluids
QIAseq solutions for NGS analysis
Predesigned or custom arrays and panels for PCR-based analysis
Genomics Workbench for accurate data analysis

Research

What solutions do you offer to standardize sample processing?

We offer specific solutions for collection, stabilization and isolation of exosomes, ccfDNA and ccfRNA or CTCs that reduce background and stabilize signals of interest. Our PAXgene, RNeasy and DNeasy technologies maintain superior sample quality for sensitive downstream applications such as qPCR and NGS – giving you relevant results and actionable insights.

How do I get results that are relevant for cancer research?

You need test systems that identify and measure specific biomarkers of interest relevant for the type of cancer. Using LNA-enhanced solutions and dedicated control systems in your research provides superior sensitivity and specificity with greater repeatability and reproducibility in qPCR and NGS – giving relevant results and actionable insights that work together from sample prep and screening through to validation and functional analysis will ease and accelerate the path to biomarker discoveries.

Can I isolate more than one analyte from a single plasma sample?

The QIAamp ccfDNA/RNA Kit offers co-isolation of ccfDNA and ccfRNA from the same plasma sample, providing excellent yield and quality of both analytes in the same eluate. This allows you to analyze both DNA and RNA mutations in the same liquid biopsy sample or can boost detection sensitivity to discover low-frequency tumor mutations.